E01P0018 Human Placenta Growth Factor ELISA kit
The Human Placenta Growth Factor ELISA kit can be used to identify samples from the human species. Placenta Growth Factor can also be called PlGF2, PGF, PGFL, PLGF, PIGF, Placental Growth Factor-Like, Vascular Endothelial Growth Factor-Related Protein, D12S1900, PlGF-2, SHGC-10760, Placental growth factor.
Product Information | |
Cat. No. | E01P0018 |
Product Name | Human Placenta Growth Factor ELISA kit |
Species | Human |
Product Size | 48 Tests / 96 Tests |
Concentration | 50-1000 pg/ml |
Sensitivity | 1.0 pg/ml |
Principal | Competitive ELISA |
Sample Volume | 100 ul |
Sample Type | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate |
Assay Time | 90 minutes |
Platform | Microplate Reader |
Conjugate | HRP |
Detection Method | Colorimetric |
Storage | 2-8°C |
Kit Components | ||
MATERIALS | SPECIFICATION | QUANTITY |
MICROTITER PLATE | 96 wells | stripwell |
ENZYME CONJUGATE | 6.0 mL | 1 vial |
STANDARD A (0.5mL) | 0 pg/mL | 1 vial |
STANDARD B (0.5mL) | 50 pg/mL | 1 vial |
STANDARD C (0.5mL) | 100 pg/mL | 1 vial |
STANDARD D (0.5mL) | 250 pg/mL | 1 vial |
STANDARD E (0.5mL) | 500 pg/mL | 1 vial |
STANDARD F (0.5mL) | 1000 pg/mL | 1 vial |
SUBSTRATE A | 6 mL | 1 vial |
SUBSTRATE B | 6 mL | 1 vial |
STOP SOLUTION | 6 mL | 1 vial |
WASH SOLUTION (100 x) | 10 mL | 1 vial |
BALANCE SOLUTION | 3 mL | 1 vial |
Principle of the Assay |
PLGF ELISA kit uses an anti-PLGF antibody and a PLGF-HRP conjugate in a competitive enzyme immunoassay method. PLGF-HRP conjugate is incubated with the assay sample and buffer in a pre-coated plate for one hour. The wells are decanted and washed five times when the incubation period is over. The HRP enzyme substrate is then incubated in the wells. The result of the enzyme-substrate reaction is a complex that is blue in hue. The process is finally stopped by adding a stop solution, causing the solution to turn yellow. In a microplate reader, the color intensity is measured spectrophotometrically at 450 nm. Due to competition for the anti-PLGF antibody binding site between PLGF from samples and PLGF-HRP conjugate, the intensity of the color is inversely proportional to the concentration of PLGF. Since the number of sites is limited, as more sites are occupied by PLGF from the sample, fewer sites are left to bind PLGF-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The PLGF concentration in each sample is interpolated from this standard curve. |
Coefficient of Variance | Intra Variation% ＜10% | |
Inter Variation% ＜12% | ||
Recovery | 95-102% | |
Linearity | Diluent Ratio | Range % |
1:2 | 93-105 | |
1:4 | 88-106 | |
1:8 | 86-108 | |
Specificity/Cross-reactivity | No significant cross-reactivity or interference between PLGF and analogues was observed. | |
E01P0018 has been referenced in the below publications：
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.
What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study.
孕中晚期PLGF、Sflt-1、sEng的MoM参考值区间研究。
The role and mechanism of asymmetric dimethylarginine in fetal growth restriction via interference with endothelial function and angiogenesis.
Related Bluegene Biotech Products
BlueGene Biotech News
